This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Siemens To Market BioPorto's Breakthrough Kidney Test

GENTOFTE, Denmark, Dec. 11, 2012 (GLOBE NEWSWIRE) -- Expectations for BioPorto Diagnostics have been high since the company launched its anticipated blockbuster product almost two years ago - the kidney injury test known as NGAL. Since then, BioPorto has worked towards solutions that would ensure broad and early market access to the test. In this regard, the first partnership on a global marketing level is now in place. This comes in the form of an informal sales partnership with Siemens Healthcare Diagnostics actively promoting BioPorto's NGAL test, while the distribution still flows through BioPorto's sales channels.

The agreement translates into excellent synergy in that Siemens is one of the world's largest suppliers of precisely the type of analyzers that BioPorto's The NGAL Test(tm) is designed to run on. The partnership creates a win-win scenario for the companies and customers. Siemens will have access to a test that their customers demand and a strategic advantage over competitors who do not offer NGAL in their test portfolios. Siemens analyzers are widely used in hospital laboratories, which ensures that the test will be economical to implement and readily available to doctors worldwide. From BioPorto's point of view, it is hard to think of a faster and more convenient way to reach customers.

Such an informal but bespoke partnership between a reagent supplier (BioPorto) and an instrument supplier (Siemens) is far from unique in the diagnostic industry. Introduction of a new diagnostic test is a long and tough process, and being first-to-market can be crucial.

But Siemens are not the only one who has set their sights on BioPorto's breakthrough test. Roche Diagnostics also confirmed their interest in NGAL and BioPorto continues to discuss possibilities for collaboration with more leading diagnostic companies.

About NGAL - the acute kidney injury test

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $94.25 -0.98%
FB $118.17 0.63%
GOOG $699.33 1.00%
TSLA $228.73 -1.50%
YHOO $35.97 -0.11%


Chart of I:DJI
DOW 17,670.54 -80.37 -0.45%
S&P 500 2,050.43 -12.94 -0.63%
NASDAQ 4,728.1080 -35.1160 -0.74%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs